메뉴 건너뛰기
Leukemia Research
Volumn 28, Issue 11, 2004, Pages 1123-1124
Myelodysplastic syndrome - An example of misguided immune surveillance?
Author keywords

[No Author keywords available]
Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;
EID: 4544363987     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.06.001     Document Type: Editorial
Times cited : (11)
References (9)
  • 1
    • 4544319588 scopus 로고    scopus 로고
    • Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells
    • Deeg HJ, Jiang PYZ, Holmberg LA, Scott B, Petersdorf EW, Appelbaum FR. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res 2004;28:1177-80.
    • (2004) Leuk Res , vol.28 , pp. 1177-1180
    • Deeg, H.J.1    Jiang, P.Y.Z.2    Holmberg, L.A.3    Scott, B.4    Petersdorf, E.W.5    Appelbaum, F.R.6
  • 2
    • 0033973769 scopus 로고    scopus 로고
    • Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology?
    • Barrett J., Saunthararajah Y., Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin. Hematol. 37:2000;15-29
    • (2000) Semin. Hematol. , vol.37 , pp. 15-29
    • Barrett, J.1    Saunthararajah, Y.2    Molldrem, J.3
  • 3
    • 0037031289 scopus 로고    scopus 로고
    • Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes
    • Molldrem J.J., Leifer E., Bahceci E., Saunthararajah Y., Rivera M., Dunbar C., et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann. Intern. Med. 137:2002;156-163
    • (2002) Ann. Intern. Med. , vol.137 , pp. 156-163
    • Molldrem, J.J.1    Leifer, E.2    Bahceci, E.3    Saunthararajah, Y.4    Rivera, M.5    Dunbar, C.6
  • 4
    • 0031888417 scopus 로고    scopus 로고
    • Cyclosporin a therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow
    • Jonašova A., Neuwirtova R., Cermak J., Vozobulova V., Mocikova K., Siskova M., et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J. Haematol. 100:1998;304-309
    • (1998) Br J. Haematol. , vol.100 , pp. 304-309
    • Jonašova, A.1    Neuwirtova, R.2    Cermak, J.3    Vozobulova, V.4    Mocikova, K.5    Siskova, M.6
  • 5
    • 0031656518 scopus 로고    scopus 로고
    • A role for tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome
    • Gersuk G.M., Beckham C., Loken M.R., Kiener P., Anderson J.E., Farrand A., et al. A role for tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J. Haematol. 103:1998;176-188
    • (1998) Br J. Haematol. , vol.103 , pp. 176-188
    • Gersuk, G.M.1    Beckham, C.2    Loken, M.R.3    Kiener, P.4    Anderson, J.E.5    Farrand, A.6
  • 6
    • 0034554786 scopus 로고    scopus 로고
    • Greenberg PL World Health Organization (WHO) international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes
    • Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., et al. Greenberg PL World Health Organization (WHO) international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 96:2000;3671-3674
    • (2000) Blood , vol.96 , pp. 3671-3674
    • Cheson, B.D.1    Bennett, J.M.2    Kantarjian, H.3    Pinto, A.4    Schiffer, C.A.5    Nimer, S.D.6
  • 7
    • 0042347518 scopus 로고    scopus 로고
    • Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis
    • Oka Y., Tsuboi A., Murakami M., Hirai M., Tominaga N., Nakajima H., et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int. J. Hematol. 78:2003;56-61
    • (2003) Int. J. Hematol. , vol.78 , pp. 56-61
    • Oka, Y.1    Tsuboi, A.2    Murakami, M.3    Hirai, M.4    Tominaga, N.5    Nakajima, H.6
  • 8
    • 0036720903 scopus 로고    scopus 로고
    • HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome
    • Saunthararajah Y., Nakamura R., Nam J.M., Robyn J., Loberiza F., Maciejewski J.P., et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 100:2002;1570-1574
    • (2002) Blood , vol.100 , pp. 1570-1574
    • Saunthararajah, Y.1    Nakamura, R.2    Nam, J.M.3    Robyn, J.4    Loberiza, F.5    MacIejewski, J.P.6
  • 9
    • 0141923848 scopus 로고    scopus 로고
    • A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome
    • Saunthararajah Y., Nakamura R., Wesley R., Wang Q.J., Barrett A.J. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood. 102:2003;3025-3027
    • (2003) Blood , vol.102 , pp. 3025-3027
    • Saunthararajah, Y.1    Nakamura, R.2    Wesley, R.3    Wang, Q.J.4    Barrett, A.J.5

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.